INVESTOR ALERT: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead the Tempus AI Class Action Lawsuit - TEM

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the credibility of Tempus AI's joint venture with SoftBank Group Corporation was compromised, creating the appearance of "round-tripping" capital to generate revenue [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca PLC reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement, raising concerns about the company's financial health [3]. - These issues collectively indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Research Report - On May 28, 2025, a research report by Spruce Point Capital Management raised significant concerns regarding Tempus AI's management, operations, and financial reporting [4]. - Following the release of this report, Tempus AI's stock price fell by more than 19% [4]. Group 3: Class Action Process - Investors who purchased Tempus AI common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit [5]. - The lead plaintiff represents the interests of all class members and can select a law firm of their choice for litigation [5]. - Participation as lead plaintiff does not affect an investor's ability to share in any potential recovery from the lawsuit [5].